Good News for ITP Patients: Ianalumab + Eltrombopag Prolongs Time to Treatment Failure VS Eltrombopag Alone
Roger Schutgens, Professor of Thrombosis and Haemostasis at UMC Utrecht, shared on LinkedIn:
“Good news for patients with ITP.
Recently, the results of the VAYHIT2 trial have been published in The New England Journal of Medicine, showing that a course of B-cell–targeted therapy (ianalumab) combined with eltrombopag significantly prolongs time to treatment failure compared to eltrombopag alone in adults with immune thrombocytopenia after first-line steroids (13 months versus 4.7 months).
More patients were able to taper and discontinue eltrombopag (62% versus 39%), supporting the concept of early, disease-modifying treatment in ITP.
It was a joyfull ride to be part of this endeavor.”
Title: Ianalumab plus Eltrombopag in Immune Thrombocytopenia
Authors: Adam Cuker, Thomas Stauch, Nichola Cooper et al.

Read the full article.
Hemostasis Today has more posts you may find interesting.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series